Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH)

Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH)

Background & Aims: The new nomenclature for metabolic dysfunction-associated steatohepatitis (MASH) requires presence of steatohepatitis in the context of at least one cardiometabolic risk. Having a health-related quality of life (HRQL) instrument validated specifically in patients with MASH...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zobair M. Younossi, Maria Stepanova, Issah Younossi, Andrei Racila
Format:	Article
Language:	English
Published:	Elsevier 2025-03-01
Series:	JHEP Reports
Subjects:	Chronic liver disease Metabolic liver disease NASH NAFLD Quality of life MASH
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589555924002805
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Association of GCKR and MBOAT7 genetic polymorphisms with non-alcoholic fatty liver disease
by: Swati U. Chavan, et al.
Published: (2024-03-01)

MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives
by: Michael Karin, et al.
Published: (2025-02-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
by: Valeria Michelle Fernández-Garibay, et al.
Published: (2025-01-01)

A (re)configuração da linguagem nos mash ups literários de Machado de Assis
by: Rebeca Fabiana Ferreira da Silva Santos, et al.
Published: (2022-01-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
by: V. T. Ivashkin, et al.
Published: (2015-12-01)

Single-Cell RNA Sequencing Reveals Macrophage Dynamics During MASH in <i>Leptin</i>-Deficient Rats
by: Xiaoming Xin, et al.
Published: (2025-01-01)

Thromboelastography parameters in chronic viral liver disease and liver resection: a retrospective study
by: Ying Di, et al.
Published: (2024-08-01)

Hyperparathyroidism in Patients with End-Stage Chronic Liver Disease (Clinical Observations)
by: A. A. Lavreniuk, et al.
Published: (2024-12-01)

Association of Breastfeeding with Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in mothers: A cross sectional survey
by: Muhammad Zafar Majeed Babar, et al.
Published: (2024-06-01)

The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
by: Xue Wang, et al.
Published: (2025-01-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)

Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet
by: Lakshmi Arivazhagan, et al.
Published: (2025-02-01)

Cellular and immune landscape of chronic liver diseases: insights from immunophenotyping
by: Shaghayegh Soleimani, et al.
Published: (2025-01-01)

Aetiology of chronic liver disease is a valuable factor for stratifying adverse outcomes of acute decompensation: prospective observational study
by: Jung Hee Kim, et al.
Published: (2025-12-01)

Magnitude, patterns, and factors associated with liver disease among clinically suspected clients in Eastern Ethiopia: hidden public health tragedy
by: Aliya Nuri, et al.
Published: (2025-01-01)

Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre‐Treatment Platelet Counts: A Retrospective Multicenter Study
by: Takayoshi Suga, et al.
Published: (2025-01-01)

Telemedicine in the tertiary liver unit: A feasibility study
by: Daniel J. Havaj, et al.
Published: (2024-12-01)

Profile of Children With Non-alcoholic Fatty Liver Disease Referred to a Hospital in Iran
by: Amin Ghanbari, et al.
Published: (2024-12-01)

Progress and prospects of elastography techniques in the evaluation of fibrosis in chronic liver disease
by: Yang Wang, et al.
Published: (2024-04-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Two faces of the same coin non alcoholic fatty liver disease; with and without diabetes: Comparative clinico pathological analysis: A cross sectional observational study
by: Syed Mushfiq, et al.
Published: (2025-01-01)

The value of sex hormones and sex hormone-binding globulin in metabolic dysfunction-associated fatty liver disease among boys with obesity
by: Ying Wang, et al.
Published: (2025-02-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Triglycerides mediate the relationships of per- and poly-fluoroalkyl substance (PFAS) exposure with nonalcoholic fatty liver disease (NAFLD) risk in US participants
by: Wenying Qiao, et al.
Published: (2025-01-01)

Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis
by: Like Zhou, et al.
Published: (2025-01-01)

A machine learning based algorithm accurately stages liver disease by quantification of arteries
by: Zhengxin Li, et al.
Published: (2025-01-01)

Mediterranean diet improves liver health but does not protect against azoxymethane-induced colon tumorigenesis compared to Western diet in A/J mice
by: Weimin Guo, et al.
Published: (2025-03-01)

Marine natural products as an important source of bioactive substances for non-alcoholic fatty liver disease management
by: Menglei Shi, et al.
Published: (2025-01-01)

Nutritional assessment using subjective global assessment identifies energy malnutrition and predicts mortality in patients with liver cirrhosis
by: Takao Miwa, et al.
Published: (2025-02-01)

The development of a food-group, tree classification method and its use in exploring dietary associations with metabolic dysfunction-associated Steatotic liver disease (MASLD) and other health-related outcomes in a UK population
by: Amina A. Alawadi, et al.
Published: (2025-03-01)

miRNAs and Hematological Markers in Non-Alcoholic Fatty Liver Disease—A New Diagnostic Path?
by: Agata Michalak, et al.
Published: (2025-01-01)

Association Between Sociodemographic Variables, Healthy Habits, and Stress with Risk Scales for Liver Disease Associated with Metabolic Dysfunction
by: Ángel Arturo López-González, et al.
Published: (2025-01-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Jessica M. Rubino, et al.
Published: (2025-01-01)

Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease
by: Mao Y, et al.
Published: (2025-01-01)

Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease
by: Doaa H. Hegazy, et al.
Published: (2024-06-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Cholestasis in Chronic Liver Disease and the Role of Ademetionine in its Treatment (Literature Review and Expert Panel Resolution)
by: K. L. Raikhelson, et al.
Published: (2024-10-01)

Liver transplantation for homozygous familial hypercholesterolemia: a retrospective analysis from Chinese experience
by: Hao-Su Zhan, et al.
Published: (2025-01-01)